Endo International plc announced Aug. 6 it completed the acquisition of DAVA Pharmaceuticals, Inc., a privately-held company specializing in generic pharmaceuticals.

The purchase price was $575 million in cash, with another $25 million contingent on certain sales milestones. DAVA Pharmaceuticals is headquartered in Fort Lee, N.J.

“We are encouraged by the earlier than expected close of the DAVA acquisition and are excited by the addition of the business to our generics portfolio.” said Rajiv De Silva, president and chief executive officer of Endo.  “The closing of DAVA further strengthens Endo’s generics platform and enhances our earnings growth and cash flow in 2014 and beyond.”

As it looks forward to prescription and procedure trends, pricing levels, inventory levels and the anticipated timing of future product launches and events, Endo is also raising its financial expectations for 2014. Endo estimates total revenue from $2.78 to $2.86 billion; diluted loss per share of between $1.56 and $1.36; adjusted diluted earnings per share between $4 and $4.20; and adjusted diluted earnings per share outstanding of $157 million.

Endo International plc has headquarters in Malvern and Dublin, Ireland. The global specialty healthcare company develops, manufactures, markets and distributes quality branded pharmaceutical, generic and device products.